Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed Phase 2 Trials for Tolvaptan (DB06212)

Also known as: Autosomal Dominant Polycystic Kidney Disease / Polycystic Kidney Disease, Autosomal Dominant / ADPKD (Autosomal Dominant Polycystic Kidney Disease) / ADPKD / Polycystic Kidney, Autosomal Dominant / Autosomal Dominant Polycystic Kidney Disease (ADPKD / Autosomal Dominant Polycystic Kidney / Kidney, Polycystic, Autosomal Dominant / Autosomal Dominant Polycystic Kidney Disease (ADPKD) / Congenital cystic kidney disease NOS / Congenital cystic kidney disease

IndicationStatusPhase
DBCOND0050861 (Autosomal Dominant Polycystic Kidney Disease (ADPKD))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00413777Tolvaptan Open-Label Pilot Efficacy, Tolerability and Safety Study in ADPKDTreatment
NCT01336972Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)Treatment
NCT02527863Effect of the Aquaretic Tolvaptan on Nitric Oxide SystemTreatment
NCT01210560Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKDTreatment
NCT00841568A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]Treatment
NCT014518278-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)Treatment